Literature DB >> 28055287

Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections.

Kristin E Linder1, David P Nicolau2, Michael D Nailor1,3.   

Abstract

OBJECTIVES: Skin and soft tissue infections (SSTIs) are among the most common bacterial diseases and represent a significant disease burden. The purpose of this study was to describe the real-world management of patients with SSTIs presenting to the emergency department (ED).
METHODS: This is a retrospective cohort study. Adult patients identified with a primary diagnosis of SSTI determined by ICD-9 codes were assessed from index presentation for up to 30 days. Records were reviewed 30 days prior to inclusion to ensure index hospitalization was captured. For recurrent visits, a similar strategy was implemented 30 days afterward.
RESULTS: Of 446 encounters screened, 357 were included; 106 (29.7%) were admitted to the hospital and 251 (70.3%) were treated outpatient. Of patients with a Charlson Comorbidity Index (CCI) score two or greater, 60.9% were treated as inpatients, whereas admission rates were 30.1% and 14.1% for patients with a CCI score of one and zero, respectively. Inpatients had an average length of stay (LOS) of 7.3 ± 7.1 days. No difference was detected in overall re-presentation to the facility 22.6% and 28.3% (p > 0.05) or in SSTI related re-presentation 10.4% and 15.1% (p > 0.05) between inpatient and outpatients. The most common gram-positive organisms identified on wound/abscess culture were MSSA (37.1% inpatients) and MRSA (66.7% outpatients). Mean total cost of care was $13,313 for inpatients and $413 for outpatients.
CONCLUSION: This analysis identifies opportunities to improve processes of care for SSTIs with the aim of decreasing LOS, reducing readmissions, and ultimately decreasing burden on the healthcare system.

Entities:  

Keywords:  Antimicrobial stewardship; readmission; skin and soft tissue infections

Mesh:

Year:  2017        PMID: 28055287     DOI: 10.1080/21548331.2017.1279519

Source DB:  PubMed          Journal:  Hosp Pract (1995)        ISSN: 2154-8331


  6 in total

1.  Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department.

Authors:  Jared Baxa; Erin McCreary; Lucas Schulz; Michael Pulia
Journal:  Am J Emerg Med       Date:  2019-09-12       Impact factor: 2.469

2.  Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.

Authors:  Safa S Almarzoky Abuhussain; Michelle A Burak; Kelsey N Kohman; Gabrielle Jacknin; Serina B Tart; Athena L V Hobbs; Danyel K Adams; Michael D Nailor; Katelyn R Keyloun; David P Nicolau; Joseph L Kuti
Journal:  BMC Health Serv Res       Date:  2018-12-04       Impact factor: 2.655

Review 3.  Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States.

Authors:  Keith S Kaye; Lindsay A Petty; Andrew F Shorr; Marya D Zilberberg
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

4.  Hospital admissions for skin and soft tissue infections in a population with endemic scabies: A prospective study in Fiji, 2018-2019.

Authors:  Li Jun Thean; Adam Jenney; Daniel Engelman; Lucia Romani; Handan Wand; Jyotishna Mudaliar; Jessica Paka; Tuliana Cua; Sera Taole; Aalisha Sahukhan; Mike Kama; Meciusela Tuicakau; Joseph Kado; Natalie Carvalho; Margot Whitfeld; John Kaldor; Andrew C Steer
Journal:  PLoS Negl Trop Dis       Date:  2020-12-09

5.  Acute Forefoot Phlegmon - A Complication of Intravenous Heroin-Addiction.

Authors:  Uwe Wollina; Torello Lotti; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2018-01-09

6.  Clinical Characteristics, Risk Factors, and Outcomes of Patients with Polymicrobial Klebsiella pneumoniae Bloodstream Infections.

Authors:  Feizhen Song; Kai Zhang; Jianjiang Huang; Zhenhua Qian; Hongwei Zhou; Jiachang Cai; Cheng Zheng; Feifei Zhou; Wei Cui; Gensheng Zhang
Journal:  Biomed Res Int       Date:  2021-06-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.